

Thomas Klockgether

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/562166/publications.pdf>

Version: 2024-02-01

120
papers

7,107
citations

53794

45
h-index

60623

81
g-index

122
all docs

122
docs citations

122
times ranked

6870
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis. <i>Movement Disorders</i> , 2022, 37, 171-181.	3.9	8
2	Quantitative susceptibility mapping reveals alterations of dentate nuclei in common types of degenerative cerebellar ataxias. <i>Brain Communications</i> , 2022, 4, fcab306.	3.3	15
3	Magnetic Resonance Imaging-Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12. <i>Movement Disorders</i> , 2022, 37, 872-873.	3.9	5
4	The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3. <i>Movement Disorders</i> , 2022, 37, 1098-1099.	3.9	0
5	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. <i>Neurology</i> , 2022, 98, .	1.1	15
6	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study. <i>NeuroImage: Clinical</i> , 2022, 34, 103025.	2.7	3
7	Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective. <i>Movement Disorders</i> , 2022, 37, 1125-1130.	3.9	21
8	Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3. <i>European Journal of Neurology</i> , 2022, 29, 2439-2452.	3.3	25
9	Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial. <i>Neurotherapeutics</i> , 2022, 19, 1259-1272.	4.4	21
10	Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (^NNERD_{ND}): Time to Move Beyond the Skin. <i>Movement Disorders</i> , 2022, 37, 1707-1718.	3.9	7
11	Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor. <i>Movement Disorders</i> , 2022, 37, 1924-1929.	3.9	6
12	Differential Temporal Dynamics of Axial and Appendicular Ataxia in ^SCA3. <i>Movement Disorders</i> , 2022, 37, 1850-1860.	3.9	11
13	A word of hope for ataxia trials in COVID-19 time and beyond. <i>Journal of Neurology</i> , 2021, 268, 2343-2345.	3.6	3
14	PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study. <i>Journal of Neurology</i> , 2021, 268, 1304-1315.	3.6	15
15	Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease. <i>Neurology</i> , 2021, 96, e1369-e1382.	1.1	93
16	Development of ^SARA_{home}, a New Video-Based Tool for the Assessment of Ataxia at Home. <i>Movement Disorders</i> , 2021, 36, 1242-1246.	3.9	36
17	Research priorities for rare neurological diseases: a representative view of patient representatives and healthcare professionals from the European Reference Network for Rare Neurological Diseases. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 135.	2.7	5
18	Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3. <i>Movement Disorders</i> , 2021, 36, 2273-2281.	3.9	37

#	ARTICLE	IF	CITATIONS
19	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 362-372.	10.2	53
20	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. <i>Frontiers in Neurology</i> , 2021, 12, 677551.	2.4	15
21	Information Extraction from German Clinical Care Documents in Context of Alzheimer's Disease. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 10717.	2.5	2
22	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. <i>Neurology</i> , 2020, 95, e3138-e3144.	1.1	18
23	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 213-218.	2.2	8
24	Effects of Rivastigmine on Patients with Spinocerebellar Ataxia Type 3: A Case Series of Five Patients. <i>Neurodegenerative Diseases</i> , 2020, 20, 104-109.	1.4	3
25	Intermediate phenotype of ATP13A2 mutation in two Chilean siblings: Towards a continuum between parkinsonism and hereditary spastic paraplegia. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 45-47.	2.2	4
26	Bi-allelic HPDL Variants Cause a Neurodegenerative Disease Ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia. <i>American Journal of Human Genetics</i> , 2020, 107, 364-373.	6.2	30
27	Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 738-747.	10.2	41
28	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e11803.	6.9	73
29	Multiple system atrophy mimicry in MRI: Watch out for paraneoplastic rhombencephalitis. <i>Journal of Clinical Neuroscience</i> , 2020, 76, 238-240.	1.5	6
30	The European Reference Network for Rare Neurological Diseases. <i>Frontiers in Neurology</i> , 2020, 11, 616569.	2.4	26
31	Structural characteristics of the central nervous system in Friedreich's ataxia: an in vivo spinal cord and brain MRI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 615-617.	1.9	33
32	Mirror movements and blepharoclonus as novel phenomena in hereditary diffuse leukoencephalopathy with spheroids. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 83-84.	2.2	3
33	Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study. <i>BMC Neurology</i> , 2019, 19, 149.	1.8	20
34	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. <i>Cerebellum</i> , 2019, 18, 896-909.	2.5	9
35	The art of making a clinical diagnosis of multiple system atrophy. <i>Brain</i> , 2019, 142, 2555-2557.	7.6	2
36	Prediction of Survival With Long-Term Disease Progression in Most Common Spinocerebellar Ataxia. <i>Movement Disorders</i> , 2019, 34, 1220-1227.	3.9	14

#	ARTICLE	IF	CITATIONS
37	Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with <i>SPG7</i> . <i>Neurology</i> , 2019, 92, e2679-e2690.	1.1	49
38	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
39	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. <i>Translational Neurodegeneration</i> , 2019, 8, 11.	8.0	10
40	Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 533-539.	2.1	17
41	Increased risk for subarachnoid hemorrhage in patients with sleep apnea. <i>Journal of Neurology</i> , 2019, 266, 1351-1357.	3.6	15
42	Disentangling motor planning and motor execution in unmedicated de novo Parkinson's disease patients: An fMRI study. <i>NeuroImage: Clinical</i> , 2019, 22, 101784.	2.7	20
43	Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study. <i>PLoS ONE</i> , 2019, 14, e0213381.	2.5	31
44	Spinocerebellar ataxia. <i>Nature Reviews Disease Primers</i> , 2019, 5, 24.	30.5	377
45	Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 559-565.	1.9	16
46	Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. <i>Lancet Neurology</i> , The, 2018, 17, 327-334.	10.2	69
47	Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. <i>Journal of Neurology</i> , 2018, 265, 2040-2051.	3.6	34
48	Teaching NeuroImages: Distinct visual anosognosia after serial lesions of Meyer loop and the lateral geniculate body. <i>Neurology</i> , 2018, 91, e94-e95.	1.1	0
49	Sporadic adult-onset ataxia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 217-225.	1.8	23
50	Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14). <i>Parkinsonism and Related Disorders</i> , 2017, 37, 111-113.	2.2	7
51	Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. <i>Brain</i> , 2017, 140, 1561-1578.	7.6	85
52	Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. <i>Neurology</i> , 2017, 89, 1043-1049.	1.1	45
53	Elevated in vivo [¹⁸ F]AV-1451 uptake in a patient with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 170-171.	3.9	49
54	Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. <i>Annals of Neurology</i> , 2016, 79, 646-658.	5.3	218

#	ARTICLE	IF	CITATIONS
55	P1-223: Functional Markers for Cerebral Norepinephrine Deficiency in Alzheimer's Disease. , 2016, 12, P492-P493.		0
56	Apolipoprotein E ϵ 4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
57	Multisystemic <i>SYNE1</i> ataxia: confirming the high frequency and extending the mutational and phenotypic spectrum. Brain, 2016, 139, e46-e46.	7.6	40
58	Update of the effect estimates for common variants associated with carotid intima media thickness within four independent samples: The Bonn IMT Family Study, the Heinz Nixdorf Recall Study, the SAPHIR Study and the Bruneck Study. Atherosclerosis, 2016, 249, 83-87.	0.8	18
59	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurology, The, 2016, 15, 1346-1354.	10.2	117
60	Wernicke encephalopathy. Neurology, 2016, 87, 1956-1957.	1.1	7
61	Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study. Annals of Clinical and Translational Neurology, 2016, 3, 572-587.	3.7	50
62	Peripheral Neuropathy in Spinocerebellar Ataxia Type 1, 2, 3, and 6. Cerebellum, 2016, 15, 165-173.	2.5	54
63	Central Pain Processing in Early-Stage Parkinson's Disease: A Laser Pain fMRI Study. PLoS ONE, 2016, 11, e0164607.	2.5	12
64	Dual task effect on postural control in patients with degenerative cerebellar disorders. Cerebellum and Ataxias, 2015, 2, 6.	1.9	20
65	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurology, The, 2015, 14, 174-182.	10.2	159
66	The preclinical stage of spinocerebellar ataxias. Neurology, 2015, 85, 96-103.	1.1	101
67	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	3.7	90
68	Does degeneration of the subthalamic nucleus prevent parkinsonism in spinocerebellar ataxia type 2 and type 3?. Brain, 2015, 138, 3139-3140.	7.6	1
69	Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurology, The, 2015, 14, 1101-1108.	10.2	213
70	Spinocerebellar ataxia type 2: progression before diagnosis. Lancet Neurology, The, 2014, 13, 445-446.	10.2	1
71	Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. Journal of Medical Genetics, 2014, 51, 479-486.	3.2	85
72	Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurology, The, 2013, 12, 650-658.	10.2	167

#	ARTICLE	IF	CITATIONS
73	Sporadic adult-onset ataxia of unknown etiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 103, 253-262.	1.8	23
74	Update on degenerative ataxias. Current Opinion in Neurology, 2011, 24, 339-345.	3.6	95
75	Milestones in ataxia. Movement Disorders, 2011, 26, 1134-1141.	3.9	78
76	Depression in Patients with Spinocerebellar Ataxia Type 3 (SCA3). Cerebellum, 2010, 9, 606-607.	2.5	1
77	Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurology, The, 2010, 9, 94-104.	10.2	204
78	Therapeutic prospects for spinocerebellar ataxia type 2 and 3. Drugs of the Future, 2009, 34, 991.	0.1	17
79	An update on inherited ataxias. Current Neurology and Neuroscience Reports, 2008, 8, 310-319.	4.2	10
80	The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum, 2008, 7, 101-105.	2.5	63
81	Ataxia. , 2008, , 405-415.		0
82	The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum, 2008, 7, 1-5.	2.5	0
83	Ataxias. Parkinsonism and Related Disorders, 2007, 13, S391-S394.	2.2	37
84	Bright light therapy in Parkinson's disease: A pilot study. Movement Disorders, 2007, 22, 1495-1498.	3.9	137
85	Reliability and validity of the scale for the assessment and rating of ataxia: A study in 64 ataxia patients. Movement Disorders, 2007, 22, 1633-1637.	3.9	161
86	Approach to the patient with ataxia. , 2005, , 699-708.		0
87	Parkinson's disease: clinical aspects. Cell and Tissue Research, 2004, 318, 115-120.	2.9	117
88	Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Experimental Neurology, 2004, 187, 86-93.	4.1	81
89	Hereditary ataxias. Handbook of Clinical Neurophysiology, 2004, 4, 655-673.	0.0	1
90	Polychemotherapy in patients with primary CNS lymphoma.. Blood, 2004, 104, 3304-3304.	1.4	0

#	ARTICLE	IF	CITATIONS
91	CNS infection with <i>C. pneumoniae</i> complicated by multiple strokes. <i>Journal of Neurology</i> , 2003, 250, 1128-1128.	3.6	0
92	Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. <i>Journal of Neurology</i> , 2001, 248, 311-314.	3.6	121
93	Phenotype assignment in symptomatic female carriers of X-linked adrenoleukodystrophy. <i>Journal of Neurology</i> , 2001, 248, 36-44.	3.6	29
94	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. <i>Movement Disorders</i> , 2001, 16, 382-395.	3.9	6
95	Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 906-916.	1.7	134
96	Recent advances in degenerative ataxias. <i>Current Opinion in Neurology</i> , 2000, 13, 451-455.	3.6	31
97	The molecular biology of the autosomal-dominant cerebellar ataxias. <i>Movement Disorders</i> , 2000, 15, 604-612.	3.9	49
98	Cell death in polyglutamine diseases. <i>Cell and Tissue Research</i> , 2000, 301, 189-204.	2.9	66
99	Pathological yawning (chasm) associated with periodic leg movements in sleep: cure by levodopa. <i>Journal of Neurology</i> , 1999, 246, 621-622.	3.6	7
100	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. <i>Annals of Neurology</i> , 1999, 45, 65-74.	5.3	255
101	The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. <i>Movement Disorders</i> , 1999, 14, 517-519.	3.9	19
102	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. <i>Annals of Neurology</i> , 1999, 45, 65-74.	5.3	152
103	An Isoform of Ataxin-3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients. <i>Brain Pathology</i> , 1998, 8, 669-679.	4.1	189
104	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. <i>Cell Death and Differentiation</i> , 1998, 5, 847-857.	11.2	93
105	Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF- β 2 dexamethasone, and p53 gene transfer. <i>Oncogene</i> , 1998, 17, 2323-2332.	5.9	30
106	A new semiautomated, three-dimensional technique allowing precise quantification of total and regional cerebellar volume using MRI. <i>Magnetic Resonance in Medicine</i> , 1998, 40, 143-151.	3.0	77
107	Induction of Nitric Oxide Synthase and Nitric Oxide-Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis Factor- α /Lipopolysaccharide. <i>Journal of Neurochemistry</i> , 1998, 71, 88-94.	3.9	186
108	Molecular and Clinical Correlations in Spinocerebellar Ataxia 2: A Study of 32 Families. <i>Human Molecular Genetics</i> , 1997, 6, 709-715.	2.9	270

#	ARTICLE	IF	CITATIONS
109	SCA6 is caused by moderate CAG expansion in the alpha1A-voltage- dependent calcium channel gene. Human Molecular Genetics, 1997, 6, 1289-1293.	2.9	104
110	Minocycline-induced benign intracranial hypertension. Journal of Neurology, 1997, 245, 55-55.	3.6	3
111	Cooperative Interception of Neuronal Apoptosis by BCL2 and BAX Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species. Journal of Neurochemistry, 1997, 69, 2075-2086.	3.9	94
112	Screening for proteins with polyglutamine expansions in autosomal dominant cerebellar ataxias. Human Molecular Genetics, 1996, 5, 1887-1892.	2.9	63
113	Significance of lipopigments with fingerprint profiles in eccrine sweat gland epithelial cells. American Journal of Medical Genetics Part A, 1995, 57, 187-190.	2.4	2
114	A defect of kinesthesia in Parkinson's disease. Movement Disorders, 1995, 10, 460-465.	3.9	226
115	Zotepine in levodopa-induced psychosis. Movement Disorders, 1995, 10, 795-797.	3.9	7
116	Visual control of arm movement in Parkinson's disease. Movement Disorders, 1994, 9, 48-56.	3.9	122
117	Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Annals of Neurology, 1993, 34, 585-593.	5.3	141
118	The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Annals of Neurology, 1991, 30, 717-723.	5.3	251
119	Dopamine control of seizure propagation: Intranigral dopamine D1 agonist SKF-38393 enhances susceptibility of seizures. Synapse, 1990, 5, 113-119.	1.2	83
120	NMDA antagonists potentiate antiparkinsonian actions of l-dopa in monoamine-depleted rats. Annals of Neurology, 1990, 28, 539-546.	5.3	290